Molecular therapy. Nucleic acids

Using adenine base editing to fix inherited retinal disease mutations in patient stem cells and lab-grown retinal tissue

Updated

Abstract

Essence

Adenine base editing corrected an AIPL1 retinal dystrophy variant in patient-derived iPSCs and retinal organoids, restoring key photoreceptor proteins.

Evidence

A proof-of-principle iPSC and retinal organoid platform experiment tested ABE correction of inherited retinal dystrophy variants, including AIPL1 c.665G>A, p.Trp222*, with modified RNA lipofection and dual-AAV delivery.

Caveat

The evidence is ex vivo and preclinical, with molecular rescue endpoints rather than vision, in vivo safety, or durability outcomes.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free